Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
about
Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumorsTargeted therapy of gastrointestinal stromal tumoursThe influence of subclonal resistance mutations on targeted cancer therapyEmerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsPersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceClinical practice guidelines for patients with gastrointestinal stromal tumor in TaiwanActivity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.Current management and prognostic features for gastrointestinal stromal tumor (GIST)p53 modulation as a therapeutic strategy in gastrointestinal stromal tumorsZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumorStrategies for modern biomarker and drug development in oncology.A case of extragastrointestinal stromal tumor complicated by severe hypoglycemia: a unique presentation of a rare tumor.[Hemato-oncological diseases].Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsAbsence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib.Gastrointestinal stromal tumor and its targeted therapeutics.Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.Incidence and survival analysis of gastrointestinal stromal tumors in shanghai: a population-based study from 2001 to 2010.Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic modelLong-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trialThe quest to overcome resistance to EGFR-targeted therapies in cancer.Imatinib: a breakthrough of targeted therapy in cancer.Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort studyIntraparietal esophageal leiomyomas diagnosed by endoscopic ultrasound-guided fine-needle aspiration cytology: Cytological and immunocytochemical features in two cases.Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumours.Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumorsEfficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.Imaging spectrum of gastrointestinal stromal tumor.Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor.Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.
P2860
Q26738567-F6A4FBBD-6EFF-49E1-A041-602FBEE3CFCEQ26745633-33567B88-6E41-436F-91BC-5F1E242908C4Q26781693-E7CC8136-6489-4D04-B692-E54B75CA571DQ26799387-B5FF3E36-71FB-40FC-98CE-7CD03DF0B28FQ26866517-50E7798F-5A56-4598-976D-57E1E0A040F3Q27027632-29086D6E-768C-41C9-BDC7-BE9CE458F12DQ27851482-9195D9BF-18EF-4ABE-9793-FE0E7F1EB7E3Q28391684-8605EB1A-20CF-431C-9285-016F54469812Q28483922-7DD2940A-9228-4C2E-B4B8-CC6FB0C0DD35Q28485315-370FFEF3-BD8C-4492-B9D9-5E8C46D9FA25Q30590270-2C4BEFA6-CE3E-4DFF-983E-06C8438BF09BQ33167956-C9001FCC-A54F-4012-B926-27E633B67EB3Q33410075-0CFF433B-64BA-43D4-AC46-4127A82D3449Q33410655-1D2AFC0D-3168-4991-958E-C5DAEF684392Q33412724-E750B7E0-8407-477E-8568-60095AC8B80CQ33561602-5D6C8974-01A8-470A-BBC3-21CC542B9C5EQ33575310-C6FB2BBD-5951-44DB-903A-31E1B7B0D745Q33579642-6941B11A-4D6D-48D9-A072-D7F29BB8F8EBQ33584749-72D5A6CE-BE1E-478D-9209-40A0E735461DQ33598205-E2567F21-FD47-4D55-BED3-BA4C5C6B9B29Q33633409-2936B10F-E692-472E-A347-5FA0105ADF3CQ33644791-A5297E2B-9DD9-439B-8AFD-A2202B689AA4Q33690657-90093FD9-41BC-4C97-B94F-1C3705504231Q33699901-9A9ADE19-9030-435C-A30D-77CBFC031C02Q33725976-E7C8744F-1473-46CE-81A7-F55091A701D1Q33747261-2FCFF6C0-7216-4EE8-9354-5E4380A30C4AQ33756542-EC98CEBB-4FBA-4DE3-89A3-831010B5B9E9Q33778291-FB02707D-E1EB-4A90-A314-D54D583E97E0Q33844776-0F9D510D-8387-4EA1-9256-5111223C9C79Q33872813-14409B95-F58E-4EE9-9FB0-ABA0B18D8B40Q33921067-8A404DD3-827B-45BE-8200-E3BCE57A0481Q34041573-9464A362-DD41-4128-8ECF-53DCE42CCEBAQ34048307-2E4BCB75-8196-4371-8070-C536395B5909Q34050275-65E2A909-096B-436C-B23A-7D84EB2CDDA1Q34069556-A4D18502-557A-4DEA-A01F-22D693D3CB0DQ34100865-80C9C871-473E-4FF2-AD1C-5B84E1818746Q34102055-2DA1F245-7C1D-4295-85F2-B2AB8BC9EA4BQ34123944-92403B8C-8B3A-4AF3-A128-9E4690FB2552Q34160550-A86454C1-0A95-49FA-ACAE-E41C7BB15EA3Q34202009-F0C3FBB1-501C-4541-9AC0-D3130F8F9A1E
P2860
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Long-term results from a rando ...... stromal tumors expressing KIT.
@ast
Long-term results from a rando ...... stromal tumors expressing KIT.
@en
Long-term results from a rando ...... stromal tumors expressing KIT.
@nl
type
label
Long-term results from a rando ...... stromal tumors expressing KIT.
@ast
Long-term results from a rando ...... stromal tumors expressing KIT.
@en
Long-term results from a rando ...... stromal tumors expressing KIT.
@nl
prefLabel
Long-term results from a rando ...... stromal tumors expressing KIT.
@ast
Long-term results from a rando ...... stromal tumors expressing KIT.
@en
Long-term results from a rando ...... stromal tumors expressing KIT.
@nl
P2093
P356
P1476
Long-term results from a rando ...... stromal tumors expressing KIT
@en
P2093
Burton Eisenberg
Charles D Blanke
Christopher D M Fletcher
Christopher L Corless
Daniela Heinz
Elisabeth Wehre
George D Demetri
Jonathan A Fletcher
Margaret von Mehren
Peter J Roberts
P304
P356
10.1200/JCO.2007.13.4403
P407
P577
2008-02-01T00:00:00Z